<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03740711</url>
  </required_header>
  <id_info>
    <org_study_id>AMC_2018_0646</org_study_id>
    <nct_id>NCT03740711</nct_id>
  </id_info>
  <brief_title>Early LA Venting During Venoaterial ECMO Support</brief_title>
  <official_title>Early Left Atrial Venting Versus Conventional Treatment For Left Ventricular Decompression During Venoarterial Extracorporeal Membrane Oxygenation Support</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The EVOLVE-ECMO(Early Left Atrial Venting Versus Conventional Treatment For Left VEntricular
      Decompression During Venoarterial ExtraCorporeal Membrane Oxygenation Support) study is a
      randomized controlled trial to evaluate the prognostic effect of early LA venting(when detect
      B-line on serial lung ultrasound) on weaning VA-ECMO support in refractory CS who receive
      VA-ECMO support. The aim of EVOLVE-ECMO trial is to test the hypothesis that early LA venting
      would result in a significant reduction in failure of weaning ECMO support in refractory CS.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 12, 2018</start_date>
  <completion_date type="Anticipated">December 3, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized controlled test</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>weaning rate of VA-ECMO</measure>
    <time_frame>during index admission</time_frame>
    <description>Weaning of VA-ECMO support</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>In hospital mortality</measure>
    <time_frame>during index admission</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse outcome due to LA venting</measure>
    <time_frame>during index admission</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Free days for mechanical ventilation</measure>
    <time_frame>during index admission</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Success rate to heart transplantation</measure>
    <time_frame>during index admission</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of improving for pulmonary edema</measure>
    <time_frame>during index admission</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cardiogenic Shock</condition>
  <condition>Extracorporeal Membrane Oxygenation Support</condition>
  <condition>Refractory Pulmonary Edema</condition>
  <arm_group>
    <arm_group_label>Early LA venting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>When detect B-line on serial lung ultrasound, we will perform early LA venting for improving LV distention in patients with refractory cardiogenic shock who received VA-ECMO support.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional LA venting</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>When detect refractory pulmonary congestion on chest radiograph or inadequate AV opening on serial echocardiography, we will perform LA venting for improving LV distention in patients with refractory cardiogenic shock who received VA-ECMO support.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Left atrial venting</intervention_name>
    <description>The contralateral femoral vein is assessed with an 7-French(Fr) sheath() and femoral artery is assessed with 5-Fr sheath( ) for fluoroscopic guidance using 5-Fr pig-tail catheter. In some cases trans-esophageal echo is used. The inter-atrial septum in punctured with a standard BRK™tran-septal needle(St. Jude Medical Inc., St. Paul, MN) under direct visualization via an 8-Fr Mullin sheath(St. Jude Medical Inc.). A SAFARI™(Boston Scientific, Galway, Ireland) guidewire is advanced into the LA. An 8-Fr Mullin-sheath is removed and atrial septostomy is performed using 21-Fr dilator. A 17-Fr or 21-Fr Biomedicus Percutaneous Femoral cannula(Medtronic Inc., Minneapolis, MN) is then placed in the LA and was attached to the ECMO circuit using a Y connector.</description>
    <arm_group_label>Conventional LA venting</arm_group_label>
    <arm_group_label>Early LA venting</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject was &gt; 18 years of age.

          -  Subjects who underwent successful VA-ECMO support

          -  Subjects with refractory cardiogenic shock who had pulmonary edema confirmed by chest
             X ray or lung sonogram.

          -  The patient or guardian agrees to the study protocol and the schedule of clinical
             follow-up, and provides informed, written consent, as approved by the appropriate
             Institutional Review Board/Ethical Committee of the respective clinical site.

        Exclusion Criteria:

          -  subject was &lt;80 years of age

          -  Pregnant and/or lactate women

          -  Subjects who underwent VA-ECMO after recent open heart surgery

          -  Subjects who underwent VA-ECMO after non-cardiogenic arrest(trauma, hypothermia,
             submersion, drug overdose, asphyxia, intracranial hemorrhage etc)

          -  Severe bleeding tendency

          -  Terminal malignancy

          -  Known severe irreversible brain damage

          -  Subject was unable to provide written informed consent or participate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min Seok Kim, PhD</last_name>
      <phone>02-3010-3948</phone>
      <email>guess124@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Hanbit Park, MD</last_name>
      <phone>02-3010-0169</phone>
      <email>phb8012@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>October 19, 2018</study_first_submitted>
  <study_first_submitted_qc>November 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2018</study_first_posted>
  <last_update_submitted>December 14, 2018</last_update_submitted>
  <last_update_submitted_qc>December 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Min-Seok Kim</investigator_full_name>
    <investigator_title>Clinical assistant professor</investigator_title>
  </responsible_party>
  <keyword>Cardiogenic shock</keyword>
  <keyword>Extracorporeal Membrane Oxygenation Support</keyword>
  <keyword>Left atrial venting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Edema</mesh_term>
    <mesh_term>Shock, Cardiogenic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

